SCHEMBL343785

SCHEMBL343785

COC(=O)C=Cc1cc(O)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 1.00
MAPT P10636 3/20 1.00
KDM4E B2RXH2 2/20 1.00
MEN1 O00255 1/20 1.00
TP53 P04637 1/20 1.00
CYP1A2 P05177 1/20 1.00
CYP2C9 P11712 1/20 1.00
HPGD P15428 1/20 1.00
ALOX15 P16050 1/20 1.00
CYP2C19 P33261 1/20 1.00
KMT2A Q03164 1/20 1.00
HSD17B10 Q99714 1/20 1.00
SNCA P37840 1/20 0.59
CA12 O43570 1/20 0.59
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
TYR P14679 1/20 0.59
CA7 P43166 1/20 0.59
CA9 Q16790 1/20 0.59
CA14 Q9ULX7 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29727537 1.00 ALDH1A1 (1.00) ALDH1A1MAPTKDM4EMEN1TP53
SCHEMBL343784 1.00 ALDH1A1 (1.00) ALDH1A1MAPTKDM4EMEN1TP53
SCHEMBL28222024 0.98 MAPT (0.97) ALDH1A1MAPTKDM4EMEN1TP53
SCHEMBL7573821 0.86 ALDH1A1 (0.76) ALDH1A1MAPTKDM4EMEN1TP53
SCHEMBL29886427 0.86 ALDH1A1 (0.76) ALDH1A1MAPTKDM4EMEN1TP53
SCHEMBL9120628 0.85 APP (0.76) ALDH1A1MAPTKDM4EMEN1TP53
SCHEMBL9120636 0.85 APP (0.76) ALDH1A1MAPTKDM4EMEN1TP53
SCHEMBL27736560 0.85 ALDH1A1 (0.73) ALDH1A1MAPTKDM4EMEN1TP53
SCHEMBL11823438 0.83 MAPT (0.71) ALDH1A1MAPTKDM4EMEN1TP53
SCHEMBL544907 0.83 MAPT (0.71) ALDH1A1MAPTKDM4EMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025049554-A1 HIF1A OR GLUT1 INHIBITION IN INFLAMMATORY SKIN DISEASES NEW YORK UNIVERSITY (US) 2025-03-06 WO claimed
WO-2009091889-A1 TREATMENT OF SKIN DISORDERS WITH EGFR INHIBITORS GEORGETOWN UNIVERSITY (US) 2009-07-23 WO claimed
EP-0809493-B1 A METHOD FOR THE TREATMENT OF HYPERPROLIFERATIVE EPITHELIAL SKIN DISEASES BY TOPICAL APPLICATION OF HYDROXYLATED AROMATIC PROTEIN CROSS-LINKING COMPOUNDS US HEALTH (US) 2002-09-11 EP claimed
EP-0809493-A1 A METHOD FOR THE TREATMENT OF HYPERPROLIFERATIVE EPITHELIAL SKIN DISEASES BY TOPICAL APPLICATION OF HYDROXYLATED AROMATIC PROTEIN CROSS-LINKING COMPOUNDS THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1997-12-03 EP claimed
US-5610185-A Method for the treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein cross-linking compounds THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1997-03-11 US claimed
WO-1996025159-A1 A METHOD FOR THE TREATMENT OF HYPERPROLIFERATIVE EPITHELIAL SKIN DISEASES BY TOPICAL APPLICATION OF HYDROXYLATED AROMATIC PROTEIN CROSS-LINKING COMPOUNDS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1996-08-22 WO claimed
US-3998851-A PREPARATION OF COUMARINS UNIVERSAL OIL PRODUCTS COMPANY (US) 1976-12-21 US claimed
JP-3109323-A None JP disclosed
WO-2026087699-A1 NEW TREATMENT OF NON-SMALL CELL LUNG CANCER PIERRE FABRE MEDICAMENT (FR) 2026-04-30 WO disclosed
EP-4578457-A1 PHARMACEUTICAL FOR TREATING AND/OR PREVENTING CANCER Toray Industries, Inc. (JP) 2025-07-02 EP disclosed
US-20250075218-A1 HIF1A OR GLUT1 INHIBITION IN INFLAMMATORY SKIN DISEASES NEW YORK UNIVERSITY (US) 2025-03-06 US disclosed
WO-2025049554-A1 HIF1A OR GLUT1 INHIBITION IN INFLAMMATORY SKIN DISEASES NEW YORK UNIVERSITY (US) 2025-03-06 WO disclosed
US-20240309327-A1 CARDIOMYOCYTE PRODUCTION METHOD MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-19 US disclosed
WO-1996025949-A1 COMPOUNDS FOR PREVENTING MULTIDRUG RESISTANCE IN CANCER CELLS CONTAINING PROTEIN KINASE INHIBITORS BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 1996-08-29 WO disclosed
EP-0728009-A1 USE OF AN AGENT WHICH MODULATES TYROSINE PHOSPHORYLATION FOR MODULATING THE PERMEABILITY OF A PSYCHOLOGICAL BARRIER Eisai Co., Ltd. (JP) 1996-08-28 EP disclosed
WO-1996025159-A1 A METHOD FOR THE TREATMENT OF HYPERPROLIFERATIVE EPITHELIAL SKIN DISEASES BY TOPICAL APPLICATION OF HYDROXYLATED AROMATIC PROTEIN CROSS-LINKING COMPOUNDS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1996-08-22 WO disclosed
WO-1996018103-A1 INHIBITION OF GLIAL CELL PROLIFERATION THE SCRIPPS RESEARCH INSTITUTE (US) 1996-06-13 WO disclosed
WO-1995013820-A1 USE OF AN AGENT WHICH MODULATES TYROSINE PHOSPHORYLATION FOR MODULATING THE PERMEABILITY OF A PSYCHOLOGICAL BARRIER EISAI CO., LTD. (JP) 1995-05-26 WO disclosed
JP-H03109323-A ANTICANCER AGENT MICROBIAL CHEM RES FOUND 1991-05-09 JP disclosed
US-3998851-A PREPARATION OF COUMARINS UNIVERSAL OIL PRODUCTS COMPANY (US) 1976-12-21 US disclosed